News & Updates
Filter by Specialty:
Guselkumab yields durable benefit in biologic-naïve PsA patients
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
High acute-to-chronic glycaemic ratio tied to worse prognosis in T2D patients with COVID-19
Type 2 diabetes (T2D) patients with COVID-19 who have elevated acute-to-chronic (A/C) glycaemic ratio are at increased risk of adverse outcomes, including in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, a study has found.
High acute-to-chronic glycaemic ratio tied to worse prognosis in T2D patients with COVID-19
23 Nov 2021
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021
Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.
Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
22 Nov 2021
Finerenone lessens HF burden among patients with CKD, diabetes
Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.
Finerenone lessens HF burden among patients with CKD, diabetes
22 Nov 2021
Obesity ups risk of early-onset colorectal cancer
Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.
Obesity ups risk of early-onset colorectal cancer
22 Nov 2021
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.